You bought on a headline about a drug that wasn’t for sale yet, then watched the price slide while you waited for the story to come true. On a bluegill fishing trip in New York’s Hudson Valley, Steven Rinella and his older son both picked up Lyme disease. His son got Bell’s palsy, a sudden paralysis on one side of the face, and got better quickly on a course of antibiotic pills. Rinella didn’t. For months he couldn’t walk down stairs without the handrail, and he couldn’t ride a bike. He ended up on antibiotics through an IV for a month.
“I thought my life had changed,” he told KFF Health News, in a story NPR ran in June 2026, “but I recovered, as far as I know.” That fishing trip was 13 years earlier. Rinella writes books and hosts the hunting show MeatEater. He also hunts turkeys, which means sitting still in tall grass for hours, and he says turkey hunters talk about ticks as much as they talk about turkeys. On NPR, Rinella said that every year he digs out a tick that’s burrowed into his skin. And having Lyme once doesn’t make you immune for good.
Pfizer and its partner Valneva said in the spring of 2026 that they’d ask regulators to approve a vaccine for Lyme. It’s three shots in the first year and a fourth about a year later. The reporter called Rinella to ask whether that many shots would put a hunter off. He said they wouldn’t, as long as the vaccine proves safe and gives real protection. Few people spend more time in the woods with ticks than hunters do, so the reporter also went to a shooting range outside St. Louis and talked to seven hunters and a hiker. Most of them said they’d consider it too, and most of those wanted to know more first about how safe it is and how well it works.
The shot isn’t approved anywhere yet. In the trial, it missed one of the goals the companies had set, because not enough people caught Lyme. The companies say it still cut cases by more than 70 percent. In August the European Medicines Agency accepted the application and started its review. Until a regulator says yes, Pfizer can’t sell it.
A price for a shot that isn’t for sale
Pfizer’s share price changes all day, trade by trade, and the people trading it already have their own views on things like the Lyme vaccine. I work out what the business is worth from the cash Pfizer has already collected. A vaccine that hasn’t sold a dose adds nothing to that. So until it sells, the vaccine can be in the price, but it isn’t in the cash. From the outside, you can’t tell which one has it right.
Pfizer’s past cash is tricky to read, because of the pandemic. In 2022, Comirnaty, the COVID vaccine it sells with BioNTech, and Paxlovid, its COVID pill, brought in $56.742 billion ($37.809 billion and $18.933 billion) of Pfizer’s $101.175 billion in revenue. That’s more than half of everything it sold. In 2025 the two brought in $6.729 billion ($4.367 billion and $2.362 billion) of $62.579 billion. Everything else Pfizer sells grew over those same years, from $44.433 billion to $55.850 billion. That’s total revenue minus the two COVID products, year by year. Pfizer’s annual report says the 2025 drop in COVID vaccine sales came from smaller deliveries under contract, lower vaccination rates in some countries, and narrower recommendations in the U.S.
Cash from operations is the money that comes in from running the business. At Pfizer it went from $29.267 billion in 2022 to $11.704 billion in 2025. In the first half of 2026 it came to $3.450 billion, up from $1.753 billion a year earlier. The quarterly report says most of that was timing, meaning when Pfizer paid its bills and when customers paid it. Earnings also changed, once you leave out the charges that don’t use cash. Pfizer’s annual report puts one price on its front page each year: what the shares held by outside investors were worth at the end of its second quarter. It was about $294 billion in 2022 and about $138 billion in 2025. So the cash and the price fell together.
Where this breaks
Because I only count cash that already came in, I see a new product late. If regulators approve the Lyme vaccine and people start getting it, the cash only shows up in what I measure after Pfizer collects it. The price can react the day a regulator says yes.
It cuts the other way too. Past cash keeps counting medicines whose patents are running out. Pfizer’s annual report puts it this way: “We anticipate a significant reduction of revenue from patent-based or regulatory exclusivity expiries in 2026 through 2030.” And when a business is going back to the size it had before the pandemic, a few years of numbers can make it look like it’s shrinking. The front-page figure also only counts outside investors’ shares, on one day. I wrote about the same gap at Meta: the difference between price and value at Meta.
Rinella’s four shots
Rinella said four shots wouldn’t stop him, if the vaccine proves safe and works. If regulators approve it, Pfizer alone would make and sell it, and it still wouldn’t keep all of what it collects. Valneva’s half-year report and annual report lay out the terms the two companies set in 2022. Pfizer would pay Valneva royalties, which are a cut of every sale. They run from 14 to 22 percent of net sales, before the offsets and reductions the contract allows. On top of that, it would pay up to $100 million in milestones, set payments as sales add up. For Valneva, those royalties and milestones are what it gets from the vaccine. For Pfizer, they’re a cost on every dose, and the cash it would collect is what’s left after Valneva’s share. In the same deal, Valneva took on 40 percent of the late-stage trial costs.
If I owned Pfizer, I’d leave the Lyme vaccine out of my numbers until Pfizer is selling it. In each quarterly report, I’d look at cash from operations and at the sales of everything besides the COVID vaccine and pill. And if the vaccine gets approved, I’d count only what Pfizer keeps after Valneva’s royalties.
To see whether Pfizer looks cheap or expensive today, pull it up in Bufetico.
While you wait for a new Pfizer drug to go on sale, Pfizer’s cash from operations shows you how the drugs it already sells are doing.
Key factsThe numbers and where they come from · 4 October 2026
- In 2025, Comirnaty and Paxlovid, Pfizer’s COVID vaccine and pill, brought in $6.729 billion of its $62.579 billion in revenue (Pfizer’s annual report). In 2022 the two brought in $56.742 billion of $101.175 billion (Pfizer’s filings).
- By the same figures, revenue from everything else Pfizer sells grew from $44.433 billion in 2022 to $55.850 billion in 2025.
- Pfizer’s cash from operations fell from $29.267 billion in 2022 to $11.704 billion in 2025 (Pfizer’s filings). In the first half of 2026 it was $3.450 billion, up from $1.753 billion (Pfizer’s quarterly report).
- Pfizer and Valneva’s Lyme disease vaccine had no approval anywhere as of October 2026, and in August 2026 the European Medicines Agency accepted the application and started its review, the companies said.
